PL3397964T3 - Kompozycje i sposoby do wykrywania i leczenia raka jajnika - Google Patents
Kompozycje i sposoby do wykrywania i leczenia raka jajnikaInfo
- Publication number
- PL3397964T3 PL3397964T3 PL17700480T PL17700480T PL3397964T3 PL 3397964 T3 PL3397964 T3 PL 3397964T3 PL 17700480 T PL17700480 T PL 17700480T PL 17700480 T PL17700480 T PL 17700480T PL 3397964 T3 PL3397964 T3 PL 3397964T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- detecting
- methods
- ovarian cancer
- treating ovarian
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307192 | 2015-12-31 | ||
| EP16305138 | 2016-02-05 | ||
| EP17700480.1A EP3397964B1 (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating ovarian cancer |
| PCT/EP2017/050033 WO2017114972A1 (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3397964T3 true PL3397964T3 (pl) | 2022-02-07 |
Family
ID=57821943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17700480T PL3397964T3 (pl) | 2015-12-31 | 2017-01-02 | Kompozycje i sposoby do wykrywania i leczenia raka jajnika |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11760808B2 (pl) |
| EP (2) | EP3954999B9 (pl) |
| JP (2) | JP6962920B2 (pl) |
| KR (2) | KR102428254B1 (pl) |
| CN (2) | CN108780091A (pl) |
| AU (2) | AU2017204682B2 (pl) |
| BR (1) | BR112018013271A2 (pl) |
| CA (2) | CA3009751A1 (pl) |
| EA (1) | EA037015B1 (pl) |
| ES (2) | ES2901602T3 (pl) |
| PL (1) | PL3397964T3 (pl) |
| SG (1) | SG11201805605TA (pl) |
| WO (1) | WO2017114972A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240018264A1 (en) * | 2015-12-31 | 2024-01-18 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating ovarian cancer |
| DK3720879T3 (da) * | 2017-12-05 | 2022-06-20 | Progastrine Et Cancers S A R L | Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer |
| US20200390913A1 (en) | 2017-12-08 | 2020-12-17 | Ecs-Biotracker Sàrl | Radiolabeled progastrin in cancer diagnosis |
| TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ｅｃｓ前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
| EP3759492A1 (en) | 2018-02-27 | 2021-01-06 | ECS-Progastrin SA | Progastrin as a biomarker for immunotherapy |
| JP7687224B2 (ja) * | 2022-01-25 | 2025-06-03 | 株式会社三洋物産 | 遊技機 |
| JP7687223B2 (ja) * | 2022-01-25 | 2025-06-03 | 株式会社三洋物産 | 遊技機 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP2567974A3 (en) | 2004-09-22 | 2013-05-22 | Cancer Advances, Inc., | Monoclonal antibodies to progastrin |
| US7854932B2 (en) | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| WO2008157383A1 (en) * | 2007-06-15 | 2008-12-24 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis of ovarian cancer and lung cancer |
| RS57966B1 (sr) * | 2009-10-16 | 2019-01-31 | Progastrine Et Cancers S A R L | Monoklonska antitela na progastrin i njihova upotreba |
| US8900588B2 (en) * | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
| WO2011116954A2 (en) | 2010-03-24 | 2011-09-29 | Bioréalités S.A.S. | Prophylaxis of colorectal and gastrointestinal cancer |
| KR101576174B1 (ko) | 2010-07-26 | 2015-12-09 | 르 라보레또레 쎄르비에르 | 간암 요법을 위한 방법 및 조성물 |
-
2017
- 2017-01-02 CN CN201780013872.3A patent/CN108780091A/zh active Pending
- 2017-01-02 US US16/067,151 patent/US11760808B2/en active Active
- 2017-01-02 CN CN202610133539.7A patent/CN122150588A/zh active Pending
- 2017-01-02 KR KR1020187020588A patent/KR102428254B1/ko active Active
- 2017-01-02 ES ES17700480T patent/ES2901602T3/es active Active
- 2017-01-02 BR BR112018013271A patent/BR112018013271A2/pt not_active IP Right Cessation
- 2017-01-02 CA CA3009751A patent/CA3009751A1/en active Pending
- 2017-01-02 SG SG11201805605TA patent/SG11201805605TA/en unknown
- 2017-01-02 AU AU2017204682A patent/AU2017204682B2/en not_active Ceased
- 2017-01-02 EP EP21199551.9A patent/EP3954999B9/en active Active
- 2017-01-02 JP JP2018534923A patent/JP6962920B2/ja active Active
- 2017-01-02 EP EP17700480.1A patent/EP3397964B1/en active Active
- 2017-01-02 ES ES21199551T patent/ES3015244T3/es active Active
- 2017-01-02 EA EA201891529A patent/EA037015B1/ru unknown
- 2017-01-02 PL PL17700480T patent/PL3397964T3/pl unknown
- 2017-01-02 WO PCT/EP2017/050033 patent/WO2017114972A1/en not_active Ceased
- 2017-01-02 CA CA3194356A patent/CA3194356C/en active Active
- 2017-01-02 KR KR1020227022682A patent/KR102507685B1/ko active Active
-
2021
- 2021-10-11 AU AU2021250840A patent/AU2021250840B2/en active Active
- 2021-10-13 JP JP2021167961A patent/JP7279761B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3009751A1 (en) | 2017-07-06 |
| US20190002582A1 (en) | 2019-01-03 |
| JP6962920B2 (ja) | 2021-11-05 |
| JP7279761B2 (ja) | 2023-05-23 |
| JP2019502923A (ja) | 2019-01-31 |
| AU2021250840A1 (en) | 2021-11-04 |
| AU2017204682B2 (en) | 2021-07-29 |
| CA3194356C (en) | 2025-04-08 |
| EP3954999B9 (en) | 2025-03-12 |
| EP3397964B1 (en) | 2021-09-29 |
| KR102507685B1 (ko) | 2023-03-08 |
| EP3954999A1 (en) | 2022-02-16 |
| EP3397964A1 (en) | 2018-11-07 |
| BR112018013271A2 (pt) | 2018-12-11 |
| KR102428254B1 (ko) | 2022-08-03 |
| SG11201805605TA (en) | 2018-07-30 |
| EA201891529A1 (ru) | 2019-01-31 |
| EP3954999B1 (en) | 2025-01-15 |
| US11760808B2 (en) | 2023-09-19 |
| ES2901602T3 (es) | 2022-03-23 |
| AU2021250840B2 (en) | 2024-06-27 |
| CN122150588A (zh) | 2026-06-05 |
| ES3015244T3 (en) | 2025-04-30 |
| WO2017114972A1 (en) | 2017-07-06 |
| EP3954999C0 (en) | 2025-01-15 |
| KR20180105647A (ko) | 2018-09-28 |
| CN108780091A (zh) | 2018-11-09 |
| JP2022009080A (ja) | 2022-01-14 |
| KR20220100100A (ko) | 2022-07-14 |
| AU2017204682A1 (en) | 2018-07-19 |
| CA3194356A1 (en) | 2017-07-06 |
| EA037015B1 (ru) | 2021-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304820A (en) | Preparations and methods for the treatment of cancer | |
| IL267247B (en) | Compositions and methods for treating cancer | |
| IL266053A (en) | Preparations and methods for the treatment of ezh2-mediated cancer | |
| ZA201706681B (en) | Compositions and methods for treating anemia | |
| IL252610A0 (en) | Methods and preparations for the treatment of cancer | |
| IL254760A (en) | A method for treating cancer | |
| SG11201708861VA (en) | Methods for treating cancer | |
| SMT202200370T1 (it) | Composizione per il trattamento del cancro | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| PT3200815T (pt) | Métodos e composições para o tratamento de cancro | |
| FI4001311T3 (fi) | Pd-l1/pd-1-vasta-aineiden yhdistelmiä kasvaimien hoitoon | |
| IL256836B (en) | Methods for treating cancer using apilimod | |
| ZA201804142B (en) | Compositions and methods for detecting and treating esophageal cancer | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| IL255022A0 (en) | Cancer treatment methods | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| ZA201703771B (en) | Compositions and methods for treating hyperkalemia | |
| IL255018A0 (en) | Cancer treatment methods | |
| IL255016A0 (en) | Cancer treatment methods | |
| ZA201802268B (en) | Methods and compositions for preventing or treating cancer | |
| SG10201912086QA (en) | Compositions and methods for treating cancer | |
| IL265537A (en) | Methods of treating ovarian cancer | |
| GB201510197D0 (en) | Method of treating ovarian cancer | |
| HK40000057A (en) | Compositions and methods for detecting and treating ovarian cancer | |
| HK1263215A1 (en) | Compositions and methods for detecting and treating gastric cancer |